EZH2 and hepatocellular carcinoma: Therefore, immunosuppressive cytokines, such as DNMT1 and EZH2, and immune cells, such as activated CD4+ T cells, monocytes, and neutrophils, may form a TIM regulatory system, representing a new target for A-HCC therapy.